Table 1 Demographic, clinical, and pathological data of the BC groups (metastatic and nonmetastatic)

 Age groups

< 45 years

14 (35%)

4 (13.3%)

> 45 years

26 (65%)

26 (86.7%)

 Menopausal state

Pre

18 (45%)

7 (23.3%)

0.063

Post

22 (55%)

23 (76.7%)

 Family history

Negative

35 (87.5%)

26 (86.7%)

0.921

Positive

5 (12.5%)

4 (13.3%)

 Oral contraceptive pills

Negative

24 (60%)

19 (63.3%)

0.780

Positive

16 (40%)

11 (36.7%)

 Tumor size

< 2

31 (77.5%)

13 (43.3%)

0.003

> 2

9 (22.5%)

17 (56.7%)

 BC pathology

Duct

34 (85%)

29 (96.7%)

0.108

Lobular

6 (15%)

1 (3.3%)

 BC subtype

Luminal A

15 (39.5%)

15 (55.6%)

0.184

Luminal B

12 (31.6%)

7 (25.9%)

0.606

Enriched

8 (21.1%)

3 (11.1%)

0.271

Basal

3 (7.9%)

2 (7.4%)

0.938

 Breast cancer grade

1

0 (0%)

4 (13.3%)

0.018

2

36 (90%)

22 (73.3%)

0.068

3

4 (10%)

4 (13.3%)

0.669

 Lymph node

Negative

14 (35%)

0 (0%)

0.0003

Positive

26 (65%)

30 (100%)

 T

T1

2 (5%)

4 (13.3%)

0.222

T2

31 (77.5%)

8 (26.7%)

< 0.0001

T3

5 (12.5%)

7 (23.3%)

0.238

T4

2 (5%)

11 (36.7%)

0.0008

 N

N0

14 (35%)

0 (0%)

0.0003

N1

24 (60%)

25 (83.3%)

0.036

N2

2 (5%)

3 (10%)

0.424

N3

0 (0%)

2 (6.7%)

0.099

 Estrogen receptor (ER)

Negative

11 (27.5%)

6 (20%)

0.472

Positive

29 (72.5%)

24 (80%)

0.658

 Progesterone receptor (PR)

Negative

13 (32.5%)

8 (26.7%)

0.602

Positive

27 (67.5%)

22 (73.3%)

 HER2

Negative

19 (47.5%)

25 (83.3%)

0.002

Positive

21 (52.5%)

5 (16.7%)

 Combined ER/PR

ER−/PR−

11 (27.5%)

5 (16.7%)

0.290

ER+/PR−

2 (5%)

3 (10%)

0.424

ER−/PR+

0 (0%)

1 (3.3%)

0.250

ER+/PR+

27 (67.5%)

21 (70%)